Liquidia Corporation Common StockLQDA

Liquidia Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare cardiopulmonary diseases. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) technology to develop precision-engineered medicines aimed at improving patient outcomes. Liquidia's portfolio includes YUTREPIA® (treprostinil inhalation powder), approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), as well as L606, an investigational sustained-release inhaled treprostinil.

liquidia.com